We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

MERIDIAN BIOSCIENCE

Meridian Bioscience manufactures, markets, and distributes diagnostic test kits, purified reagents and biopharmaceuti... read more Featured Products: More products

Download Mobile App





Meridian Demonstrates State-of-the-Art Urea Breath Test System at AACC 2022

By LabMedica International staff writers
Posted on 27 Jul 2022
Print article
Image: BreathID platform offers a cost-effective clinical diagnostic solution (Photo courtesy of Meridian)
Image: BreathID platform offers a cost-effective clinical diagnostic solution (Photo courtesy of Meridian)

Meridian Bioscience Inc. (Cincinnati, OH, USA) is attending the 73rd AACC Annual Scientific Meeting & Clinical Lab Expo where the company will exhibit its state-of-the-art urea breath test system alongside its advanced fluorescent immunoassay and molecular platforms.

At AACC 2022, Meridian will display its state-of-the-art BreathID Hp Lab urea breath test system for H. pylori detection that intuitively combines market-leading diagnostic accuracy with efficient automation and fast batch-test analysis for maximizing large lab testing throughput. The system’s built-in automated monitoring manages batch analysis, moving from test sample to test sample while noting any sample errors for post-batch handling. The BreathID platform can be used in conjunction with other Meridian H. pylori platforms for a total testing solution across the health system.

Meridian is also exhibiting the Curian fluorescent immunoassay platform focused on gastrointestinal testing that is packaged in a small footprint to improve hospital operational efficiencies. Curian provides healthcare systems a rapid fluorescent immunoassay diagnostic solution with a standardized, simplified workflow that eliminates subjectivity. Laboratories can eliminate workflow burdens and achieve optimal efficiency while delivering top-of-the-line patient care.

Also on display at Meridian’s booth will be the company’s Revogene flexible molecular platform capable of single analyte and multiplex testing that is packaged in a small footprint, and can help standardize testing throughout the health system. Revogene is a fully automated molecular platform that features single and multiplex testing capabilities with minimal hands-on time. The flexible, scalable platform comes with a broad test menu for the detection of hospital inquired infections, gastrointestinal, respiratory, and neonatal diseases.
 

Related Links:
Meridian Bioscience Inc. 

New
Platinum Member
Flu SARS-CoV-2 Combo Test
OSOM® Flu SARS-CoV-2 Combo Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Magnetic Bead Separation Modules
MAG and HEATMAG

Print article
77 ELEKTRONIKA

Channels

Clinical Chemistry

view channel
Image: PhD student and first author Tarek Eissa has analyzed thousands of molecular fingerprints (Photo courtesy of Thorsten Naeser / MPQ / Attoworld)

Screening Tool Detects Multiple Health Conditions from Single Blood Drop

Infrared spectroscopy, a method using infrared light to study the molecular composition of substances, has been a foundational tool in chemistry for decades, functioning similarly to a molecular fingerprinting... Read more

Molecular Diagnostics

view channel
Image: Researchers have found the first evidence of testing for the alpha-synuclein protein in blood samples via seed amplification assay (Photo courtesy of Shutterstock)

Blood Test to Detect Alpha-Synuclein Protein Could Revolutionize Parkinson's Disease Diagnostics

Currently, Parkinson's disease (PD) is identified through clinical diagnosis, typically at a later stage in the disease's progression. There is a pressing need for an objective and quantifiable biomarker... Read more

Hematology

view channel
Image: The Truvian diagnostic platform combines clinical chemistry, immunoassay and hematology testing in a single run (Photo courtesy of Truvian Health)

Automated Benchtop System to Bring Blood Testing To Anyone, Anywhere

Almost all medical decisions are dependent upon laboratory test results, which are essential for disease prevention and the management of chronic illnesses. However, routine blood testing remains limited worldwide.... Read more

Immunology

view channel
Image: The blood test measures lymphocytes  to guide the use of multiple myeloma immunotherapy (Photo courtesy of 123RF)

Simple Blood Test Identifies Multiple Myeloma Patients Likely to Benefit from CAR-T Immunotherapy

Multiple myeloma, a type of blood cancer originating from plasma cells in the bone marrow, sees almost all patients experiencing a relapse at some stage. This means that the cancer returns even after initially... Read more

Microbiology

view channel
Image: Ultra-Rapid Antimicrobial Susceptibility Testing (uRAST) revolutionizing traditional antibiotic susceptibility testing (Photo courtesy of Seoul National University)

Ultra-Rapid Culture-Free Sepsis Test Reduces Testing Time from Days to Hours

Sepsis, a critical emergency condition, results from an overactive inflammatory response to pathogens like bacteria or fungi in the blood, leading to organ damage and the possibility of sudden death.... Read more

Pathology

view channel
Image: The AI model can distinguish different stages of DCIS from inexpensive and readily available breast tissue images (Photo courtesy of David A. Litman/Shutterstock)

AI Model Identifies Breast Tumor Stages Likely To Progress to Invasive Cancer

Ductal carcinoma in situ (DCIS) is a non-invasive type of tumor that can sometimes progress to a more lethal form of breast cancer and represents about 25% of all breast cancer cases. Between 30% and 50%... Read more

Industry

view channel
Image: Beckman Coulter will utilize the ALZpath pTau217 antibody to detect key biomarker for Alzheimer\'s disease on its DxI 9000 immunoassay analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter Licenses Alzpath's Proprietary P-tau 217 Antibody to Develop Alzheimer's Blood Test

Cognitive assessments have traditionally been the primary method for diagnosing Alzheimer’s disease, but this approach has its limitations as symptoms become apparent only after significant brain changes... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.